Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rowin, J.
Right arrow Articles by Christadoss, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowin, J.
Right arrow Articles by Christadoss, P.
Related Collections
Right arrow Myasthenia
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrowRelated Article
NEUROLOGY 2004;63:2390-2392
© 2004 American Academy of Neurology
Brief Communications

Etanercept treatment in corticosteroid-dependent myasthenia gravis

J. Rowin, MD, M. N. Meriggioli, MD, E. Tüzün, MD, S. Leurgans, PhD and P. Christadoss, MD

From the Section of Neuromuscular Disease (Drs. Rowin and Meriggioli), Department of Neurology and Rehabilitation, University of Illinois at Chicago, and Department of Neurological Sciences (Dr. Leurgans), Rush University Medical Center, Chicago, IL, and Department of Microbiology and Immunology (Drs. Tüzün and Christadoss), University of Texas at Galveston.

Address correspondence and reprint requests to Dr. M.N. Meriggioli, Section of Neuromuscular Disease, Department of Neurology and Rehabilitation, University of Illinois at Chicago, 912 S. Wood St., 855N NPI, M/C 796, Chicago, IL 60612-7330; e-mail: mmerig{at}uic.edu

The authors report a prospective pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with eight completing the 6-month trial. Two patients were withdrawn owing to disease worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement.

Received May 11, 2004. Accepted in final form August 2, 2004.


Related Article

December 28 Highlights
Neurology 2004 63: 2202-2003. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 PNHome page
D Hilton-Jones
When the patient fails to respond to treatment: myasthenia gravis
Practical Neurology, November 1, 2007; 7(6): 405 - 411.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Yang, E. Tuzun, D. Alagappan, X. Yu, B. G. Scott, A. Ischenko, and P. Christadoss
IL-1 Receptor Antagonist-Mediated Therapeutic Effect in Murine Myasthenia Gravis Is Associated with Suppressed Serum Proinflammatory Cytokines, C3, and Anti-Acetylcholine Receptor IgG1
J. Immunol., August 1, 2005; 175(3): 2018 - 2025.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.